Table 3.
Summary of the 24-h mean systolic ambulatory blood pressure (mmHg) assessments at week 4 with various antihypertensive treatments (ITT population)*
| LSM (SE) change from baseline at week 4 |
||||||
|---|---|---|---|---|---|---|
| Parameter | N | Lumiracoxib 100 mg od | N | Ibuprofen 600 mg tid | Estimated difference (95% CI) | p-Value |
| Overall population | 363 | −2.7 (0.4) | 359 | 2.2 (0.4) | −5.0 (−6.1 to −3.8) | < 0.001 |
| Subgroups | ||||||
| ARB | ||||||
| Monotherapy | 53 | −3.5 (1.2) | 45 | 4.6 (1.3) | −8.1 (−11.5, −4.7) | < 0.001 |
| Any use† | 138 | −2.6 (0.7) | 130 | 3.5 (0.8) | −6.1 (−8.2, −4.0) | < 0.001 |
| ACEI | ||||||
| Monotherapy | 39 | −4.6 (1.3) | 37 | 3.7 (1.4) | −8.2 (−12.1, −4.4) | < 0.001 |
| Any use† | 105 | −4.0 (0.7) | 110 | 2.0 (0.7) | −5.9 (−7.9, −3.9) | < 0.001 |
| Beta-blocker | ||||||
| Monotherapy | 35 | −3.0 (1.1) | 22 | 2.8 (1.4) | −5.8 (−9.3, −2.3) | 0.002 |
| Any use† | 109 | −2.4 (0.7) | 109 | 1.6 (0.7) | −4.0 (−6.0, −2.1) | < 0.001 |
| Calcium channel blockers | ||||||
| Monotherapy | 17 | −1.0 (1.4) | 17 | 1.8 (1.4) | −2.8 (−6.9, 1.4) | 0.184 |
| Any use† | 85 | −2.3 (0.7) | 66 | 1.2 (0.8) | −3.4 (−5.4, −1.5) | < 0.001 |
| Diuretic | ||||||
| Monotherapy | 12 | −1.5 (2.3) | 17 | 2.1 (1.9) | −3.6 (−9.8, 2.6) | 0.241 |
| Any use† | 183 | −2.4 (0.6) | 194 | 1.4 (0.6) | −3.8 (−5.4, −2.3) | < 0.001 |
| Any | ||||||
| Monotherapy | 156 | −3.2 (0.6) | 138 | 3.4 (0.7) | −6.7 (−8.5, −4.9) | < 0.001 |
| Combination‡ | 206 | −2.5 (0.5) | 217 | 1.3 (0.5) | −3.9 (−5.3, −2.4) | < 0.001 |
*
Primary end-point.
†
Monotherapy or free and fixed-dose combinations.
‡
Free or fixed-dose.
ACEI, angiotensin-converting enzyme inhibitor; ARBs, angiotensin receptor blockers; CI, confidence interval; MSABP, mean systolic ambulatory blood pressure; ITT, intention-to-treat; LSM, least squares mean; od, once daily; SE, standard error; tid, thrice daily.